The biotech start-up EvlaBio secures seed financing totalling 21 million euros. This makes this seed financing round one of the largest of its kind for a biotechnology company in Germany. This success was made possible by the development of a specific therapeutic antibody at the Lead Discovery Center GmbH (LDC), a translational research company at the Biomedical Centre Dortmund (BMZ). Photo: Lead Discovery Centre
The aim of the start-up company EvlaBio, based in Düsseldorf and Zurich, is to develop a monoclonal antibody for the treatment of left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD).
"Despite medical advances, there is still a significant clinical need in the treatment of LVH in the context of CKD. Our technology intervenes directly at the cardiomyocyte level in a pathologically active signalling pathway and has the potential to improve the quality of life of millions of people affected," explains Wenzel von der Heydte, CEO and co-founder of EvlaBio.
The EvlaBio research programme was originally initiated by the LDC, a spin-off of Max Planck Innovation, and further developed together with the KHAN Technology Transfer Fund I.
The seed round was led by Kurma Partners, AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF and will enable EvlaBio to complete preclinical development and progress towards IND-approvable studies.
Here you can find the press release of EvlaBio.
About Lead Discovery Centre GmbH
Since the foundation In 2008, LDC rand 130 drug discovery projects launched. LDC a Paving the way for innovative medicines for diseases with a high medical need.
As a translational drug discovery company, LDC takes promising innovative research projects and, together with over 100 academic partners, transforms them into medically and commercially attractive drug candidates.
